US Tech Wake-Up: The Only Morning Briefing You Need

Isomorphic Labs just raised two-point-one BILLION dollars. On yesterday's show, we covered the big AI power moves, and folks, this is what a power move looks like. This isn't for a social media app or another chatbot—it's to use artificial intelligence to design brand new medicines from scratch. We are living in wild times. Alright, let's get a pulse on the rest of the landscape, because everything is moving. The European Union is now negotiating to join a US-led alliance called Pax Silica. The goal? To build a trusted network for semiconductors, AI infrastructure, and critical minerals—basically, to create a tech supply chain that doesn't depend on China. Most of the EU is leaning in, but France is still on the fence, which tells you everything you need to know about how messy this is going to be.

Meanwhile, IBM just dropped two new Red Hat services on its cloud. Look, this is the less glamorous side of AI, but it's where the money is. IBM's CTO basically said, "Everyone's got AI pilots, but nobody knows how to put them into production." These new services are the bridge from experiment to actual, functioning enterprise AI. And then there's Veeam, which just launched a platform to... get this... govern autonomous AI agents. They claim that in most companies, these software agents now outnumber human employees eighty-two to one. Eighty-two to one! And most of them have way too much access. So Veeam is building the compliance and security layer for your new robot workforce. And finally, just to prove the health-AI trend is real, a company called Forus raised a hundred and sixty million dollars to build an AI network connecting doctors, pharmacies, and patients to speed up treatment delivery.

Okay. Let's go back to that two-point-one billion dollars for Isomorphic Labs. This is Alphabet's baby, spun out of DeepMind, and run by the legendary Sir Demis Hassabis. They've already made insane progress using AI to predict the structure of proteins—the building blocks of life. This funding round, led by Thrive Capital and packed with heavyweights like Alphabet itself and the UK's Sovereign AI Fund, isn't a bet. It's a coronation. They're not just trying to find one drug. They're trying to reinvent the entire discovery process, which can take a decade and cost billions for a single success. Ruth Porat, Alphabet's President, said this cash is to "bring important interventions to market with greater speed." That's the driest possible way to say "cure diseases faster." This is AI's moonshot moment for medicine.

But here's the part that gives me whiplash. While Isomorphic is building the AI that could literally save your life, Veeam is raising a giant red flag about the AI we already have. Think about that eighty-two-to-one number. Eighty-two software agents for every one human employee. These aren't just chatbots answering customer questions. They are autonomous systems buying things, moving data, and executing commands at machine speed. Veeam’s CEO, Anand Eswaran, had the line of the day. He said, "The infrastructure to deploy AI exists. The infrastructure to trust it doesn’t." That hits hard. We have spent the last two years building the most powerful, autonomous tools in history, and we've given them the keys to the kingdom with almost zero oversight.

It's like handing a toddler a credit card with no limit. So Veeam is building the platform for resilience, governance, and privacy—the missing layer of trust. So you've got these two parallel realities happening at once. On one hand, you have the brightest minds in the world using billions of dollars to build AI that will solve humanity's most complex problems. It's optimistic. It's inspiring. It's the future we were promised. And on the other hand, you have the frantic, almost panicked race to build the brakes for the AI we've already let loose in our own companies. We are simultaneously building the most powerful engines in human history... and just now starting to sketch the blueprints for the emergency brake.